Collegium Pharmaceutical, Inc. (NASDAQ:COLL) EVP Shirley R. Kuhlmann Sells 26,067 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) EVP Shirley R. Kuhlmann sold 26,067 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total value of $742,909.50. Following the completion of the transaction, the executive vice president now owns 108,137 shares of the company's stock, valued at approximately $3,081,904.50. This represents a 19.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Collegium Pharmaceutical Stock Performance

COLL traded up $0.75 on Monday, reaching $29.66. The company had a trading volume of 388,231 shares, compared to its average volume of 422,500. The stock has a market cap of $933.87 million, a P/E ratio of 12.78 and a beta of 0.99. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The company's fifty day moving average is $30.78 and its 200 day moving average is $33.19.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on COLL. HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a report on Friday, January 10th. Finally, Piper Sandler cut their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $43.60.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently modified their holdings of the business. Invesco Ltd. boosted its holdings in Collegium Pharmaceutical by 19.5% in the 4th quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock valued at $50,876,000 after purchasing an additional 289,335 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Collegium Pharmaceutical by 319.4% in the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock valued at $8,341,000 after buying an additional 221,903 shares during the period. Victory Capital Management Inc. grew its position in Collegium Pharmaceutical by 43.6% during the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company's stock worth $27,461,000 after buying an additional 215,874 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Collegium Pharmaceutical by 173.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company's stock worth $10,711,000 after acquiring an additional 175,892 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Collegium Pharmaceutical in the 4th quarter valued at $3,489,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.